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’INTRODUCTION
The neglected disease human African trypanosomiasis (HAT),
or African sleeping sickness, is caused by two subspecies of the
protozoan parasite Trypanosoma brucei. If not successfully treated,
HAT is fatal, and it is estimated to be responsible for about 30000
deathseachyearinsub-SaharanAfrica.
1Thereisnoeﬀectivevaccine
for HAT, and the current therapeutics used to treat the disease
possess a number of limitations including high toxicity, eﬃcacy
against only a single T. brucei subspecies, and the emergence of
resistance.
1,2Undoubtedly,thereisanurgentneedfortheidentiﬁca-
tion and development of new antitrypanosomal compounds.
T. brucei and a number of related parasites utilize a redox
metabolism based around the dithiol trypanothione [N
1,N
8-
bis(glutathionyl)spermidine] (Figure 1), which is absent in
humans.
3 Therefore, the enzymes involved in this redox path-
way are considered to be attractive targets for the development
of new antitrypanosomal drugs.
4,5 One component of the try-
panothione-based redox pathway is trypanothione reductase
(TryR, EC 1.8.1.12), an NADPH-dependent disulﬁde oxidor-
eductase, which is responsible for reducing trypanothione disul-
ﬁde (T[S]2) to dihydro-trypanothione (T[SH]2) (Figure 1).
3
This reduction is analogous to that performed by glutathione
reductase (GR, EC 1.8.1.7) in most organisms, including hu-
mans.However,theactivesitesofthetwoenzymeshaveopposite
net charges, facilitating the development of inhibitors selective
for TryR over GR.
6 Trypanothione provides reducing equiva-
lents either directly or via tryparedoxin for several essential
enzymes that protect T. brucei parasites from oxidative damage.
7
Genetic studies have demonstrated that TryR activity is
essential for T. brucei parasites to grow in culture and to be
infective in an animal disease model.
8 Therefore, TryR is a
genetically validated drug target, one important criterion in drug
target assessment.
9,10 In addition, TryR inhibitors with diverse
core-scaﬀolds have been reported.
9,11 19 However, many of the
reportedinhibitorsareoflowpotency(TryRIC50>1μM),orare
not drug-like (e.g., mol wt >500) and therefore do not represent
suitable starting points for the development of antitrypanosomal
drugs. This requirement for high molecular weight compounds
to eﬀectively inhibit TryR may in part be a consequence of
Received: March 18, 2011
ABSTRACT: Trypanothione reductase (TryR) is a genetically
validated drug target in the parasite Trypanosoma brucei, the
causative agent of human African trypanosomiasis. Here we
report the discovery, synthesis, and development of a novel
series of TryR inhibitors based on a 3,4-dihydroquinazoline
scaﬀold. In addition, a high resolution crystal structure of TryR,
alone and in complex with substrates and inhibitors from this
series, is presented. This represents the ﬁrst report of a high
resolution complex between a noncovalent ligand and this
enzyme. Structural studies revealed that upon ligand binding
the enzymeundergoes a conformational changeto create a new
subpocket which is occupied by an aryl group on the ligand.
Therefore, the inhibitor, in eﬀect, creates its own small binding pocket within the otherwise large, solvent exposed active site. The
TryR ligand structure was subsequently used to guide the synthesis of inhibitors, including analogues that challenged the induced
subpocket. This resulted in the development of inhibitors with improved potency against both TryR and T. brucei parasites in a
whole cell assay.6515 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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series by both high-throughput
9,13 and virtual screening,
21,22
the development of these hits into submicromolar inhibitors
has been limited by the lack of crystallographic information
required to guide structure-based drug design. None of the
proposed TryR inhibitor binding modes derived from docking
experiments
11,21,23 25 have been veriﬁed by structural techni-
ques and the only high-resolution TryR inhibitor complex
that has been reported is that from a covalent adduct between
quinacrine mustard and T. cruzi TryR.
26
Inthiscurrentarticle,wereportthesynthesisandevaluationof
a series of novel T. brucei TryR inhibitors based on the 3,4-
dihydroquinazoline core structure (Figure 2). This series was
identiﬁed from a high-throughput screen against Trypanosoma
cruzi TryR
13and subsequently conﬁrmed toalso inhibitT.brucei
TryR. Inhibition data are reported for all analogues against T.
brucei TryR and for selected compounds against the parasite
in a whole cell assay. The structure activity relationship (SAR)
derived from the in vitro data is discussed. Additionally, the key
molecular interactions formed between the 3,4-dihydroquinazo-
lines and TryR have been identiﬁed by determining the X-ray
crystalstructureofinhibitorsincomplexwithT.bruceiTryR.The
ligandedstructureswereusedtoguidefurthersynthesis,resulting
in the preparation of analogues with increased potency against
the target enzyme.
’CHEMISTRY
The general synthetic route used to access the 3,4-dihydro-




2-aminobenzophenones (2a d) were converted to amides
(3a d) by treatment with functionalized acid chlorides. The
ketone functionality of 3a d was subsequently reacted with
primary amines under microwave irradiation to aﬀord substi-
tutedimines(4a k,7a d,10,12,14b d,20).Reductionofthe
imines with NaBH4 gave the corresponding secondary amines,
fromwhichthe3,4-dihydroquinazolinescouldbeaccessedeither
by reaction with POCl3 or by temperature-assisted cyclization.
Alternatively, both the imine reduction and cyclization reactions
could be achieved in a single pot by treating the imines with
NaBH4 in reﬂuxing EtOH (Scheme 1). This synthetic route
proved to be tolerant of a variety of substituents and was used to
prepare a number of small compound arrays and individual
compounds. The full range of compounds prepared is shown
in Tables 2 5.
To prepare two small collections of substituted amide analo-
gues (Scheme 2) the t-Boc-protected analogues 11a and 13a
were ﬁrst prepared by following the chemical transformations
outlined above (Scheme 1). Deprotection of 11a and 13a by
treatment with excess HCl, followed by reaction of the resultant
amines with a collection of acid chloride building blocks, gave
amides 11b h and 13b h, respectively (Scheme 2).
Variation at the R
6 position required the synthesis of inter-




28 (Scheme S4 of the Supporting In-
formation). Using the 6-bromo derivative (15c), it was possible
to introduce aromatic rings at the 6-position using Suzuki
chemistry
29 (Scheme 3). Similarly, reaction of the 8-bromo-de-
rivative 18 under Suzuki reaction conditions
29 gave the 8-phenyl
analogue (19) (Scheme 3).
To further investigate the series, it was necessary to prepare
analogues where the substituent R
4 was varied. This required
substituted 2-aminobenzophenone starting materials, which
weresynthesizedbythreediﬀerentroutes(Scheme4).Following
a literature sequence, anthranilate 23 was converted to benzox-
azinone 24
30 and subsequently reacted with p-tolylmagnesium
bromide to give benzophenone 27a in an 18% yield.
31 Benzo-
phenone 27a was then converted to quinazoline analogue 29a
using the general reaction sequence described above. Given the
poor yieldof 27a, an improved two-step synthesis was employed
for the preparation of 27b e (Scheme 4). Brieﬂy, anthranilate
23 wastreatedwithsubstitutedaryl lithiums followed byTMSCl
to give the substituted 2-aminobenzophenones 26b e.
32 Sub-
sequent reaction with AcCl gave amides 27b e, which were
converted to 29b e as outlined in Scheme 4. Alternatively,
benzophenoneanaloguescouldbeaccessedbyreactingGrignard
reagents with nitrile 25, followed by hydrolysis of the resultant
imine (Scheme 4). This was useful for the preparation of
analogues that were not accessible by other routes (Scheme S6
of the Supporting Information).
The route used to prepare each of 29b f required four
dedicated steps from 23,o r25 making this route unsuitable for
the rapid generation of analogues. Therefore, a shorter, more
suitableroute(Scheme5)wasdevelopedforthepreparationofa




of T. cruzi and T. brucei TryR (see Table 1).6516 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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smallcollectionofR
4analogues(32a g).Benzoxazinone24was
converted into quinazolinone 30 by reaction with 1-(2-ami-
noethyl)piperidine and subsequent microwave-assisted cyclocon-
densation.
33 Reaction of30with either substituted phenylGrignard
reagents or benzylmagnesium chloride aﬀorded the 4-substituted
3,4-dihydroquinazolin-4-ols 31a h.
34 However, the attempted
reactions between 30 and cyclohexylmagnesium or cyclopentyl-
magnesium chloride were unsuccessful, suggesting a limitation in
the range of R
4 groups that could be incorporated via this route.
Benzylic alcohols 31a g were subsequently reduced by treatment
with Et3SiH and BF33OEt2 to give the desired 3,4-dihydroquina-
zolines 32a g.
Scheme 2. Synthetic Routes for the Preparation of Two 3,4-Dihydroquinazoline Amide Arrays (For Additional Details, See
Scheme S3 of the Supporting Information; For Details of Individual Substituents, See Table 3)
a
aReagents and conditions: (i) (1) HCl, dioxane/THF, 25 C, 2 h; (2) RCOCl, pyridine, CH2Cl2,4 0C, 16 h.
Scheme 1. General Synthetic Route to 3,4-Dihydroquinazoline Analogues (Also See Schemes S1, S3, and S4 of the Supporting
Information; For Details of Individual Substituents, See Tables 2 5; Note That Products of This Route Are Racemates)
a
aReagents and conditions: (i) R
2COCl, DMAP, pyridine, CH2Cl2,2 5C, 16 h; (ii) H2N(CH2)nR
3, EtOH, 160 C (MW), 2 h; (iii) NaBH4, DMF, or
EtOH, 50 C, 16 h; (iv) POCl3,C H 2Cl2,0  25 C, 16 h; (v) EtOH, 160 C (MW) 2 h; (vi) NaBH4, EtOH, 78 C, 16 h.
Scheme 3. Synthetic Routes for the Preparation of Bi-aryl 3,4-Dihydroquinazoline Analogues (See Schemes S4 and S5 of the
Supporting Information for the Synthesis of 15c and 18, Respectively; For Details of Individual Substituents, See Table 4)
a
aReagents and conditions: (i) (HO)2B-R
6/8,K 3PO4, Pd(PPh3)4, dioxane/H2O, 120 C (MW), 0.5 h.6517 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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The two C4 methoxyphenyl analogues (32c and 29d)w e r e
converted into the corresponding phenol analogues (35 and 36)
by treatment with BBr3 (Scheme S8 of the Supporting In-
formation).Thisgaveatotalof15analoguescontainingdiﬀerent
C4 substitutions (Table 5).
’BIOLOGICAL ASSAYS
Compounds were assayed againstrecombinantT. brucei TryR
usingaspectrophotometricnonenzymatically coupled assay.
35,36
In this assay, the activity of TyrR is coupled to the reduction of
DTNB (5,50-dithiobis-(2-nitrobenzoic acid)) to 2TNB
 , which
canbemeasuredasanincreaseinabsorbanceat412nm(FigureS1
of the Supporting Information). The same assay was used to
conductamoredetailedkineticanalysisinordertodeterminethe
mode of inhibition of selected inhibitors (see section 2.2 of the
Supporting Information for more details). Selected compounds
were also assayed against bloodstream form T. brucei using the
resazurin ﬂuorescence-based cell viability assay
37 modiﬁed from
a previous method.
38 In addition, the compounds were as-
sayed using a similar protocol against MRC-5 cells as an indica-
tor of mammalian toxicity. Compound 1a was also assayed
against human GR using a protocol conceptually similar to the
TryR assay.
’RESULTS AND DISCUSSION
Identification and Validation of the 3,4-Dihydroquinazo-
lines as a Hit Series. A high-throughput screen of 100000 com-
pounds against T. cruzi TryR
13 identified the 3,4-dihydroquina-
zolines 1a and 1b (Figure 2, Table 1) as low potency inhibitors
Scheme 4. Synthetic Routes for the Preparation of 3,4-Dihydroquinazoline Analogues Containing Diﬀerent Substitutions at R
4
(29a f) (Also See Scheme S7 of the Supporting Information; For Details of Individual Substituents, See Table 5)
a
aReagents and conditions: (i) Ac2O, 138 C, 2 h; (ii) (1) R
4Li, THF, 0 C, 2 h; (2) TMSCl, 0 25 C, 15 min; (iii) R
4 MgX, Et2O, 0 25 C, 16 h;
(iv) AcCl, DMAP, pyridine, CH2Cl2,2 5C, 16 h; (v) R
4 MgX, THF, 25 C, 30 min, 67 C, 2 h; (vi) H2N(CH2)nCH2R
3, EtOH, 160 C (MW), 2 h;
(vii) NaBH4, EtOH, 78 C, 16 h.
Scheme 5. Shortened Synthetic Strategy for the Preparation of 3,4-Dihydroquinazoline Analogues Substituted at R
4 (For Details
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(IC50 19 and 38 μM, respectively). The 3,4-dihydroquinazolines
were considered promising screening hits for further investiga-
tion due to their low molecular weights (373 and 308), reason-
able ligand efficiencies (0.28 and 0.27 kcal mol
 1 per non-H
atom, respectively), and low polar surface area, an important
propertydue to the requirementfor blood brain barrierperme-
ability to treat stage 2 HAT. (As defined here, ligand efficiency =
free energy of binding (ΔG)/number of non-hydrogen (“heavy”)
atoms, where ΔG =  RT3lnKd with R = 1.987 cal K
 1 mol
 1;
T = 300 K; and assuming Kd ∼ IC50 (M).)
To determine the validity of this series as a starting point for
the development of a lead compound for the treatment of HAT,
1a,1b,andasmallcollectionofcommerciallyavailableanalogues
(1c n) were assayed against T. brucei TryR (Table 1). The hit
compounds 1a and 1b were found to have IC50 values of 6.8 and
67μM,respectively,conﬁrmingtheiractivityagainsttheT.brucei
enzyme. The similar levels of activity observed for 1a and 1b
against T. cruzi and T. brucei TryR (<3-fold diﬀerence) is as
expected given the high degree of sequence identity between
TryR in the two species (83% at the amino acid level overall,
100% for active site residues). The remainder of the commercial
analogues (1c n) display a range of TryR inhibitory activities
(IC50 9.4 to >100 μM, Table 1). Although no analogues with
improved potency were identiﬁed, it was possible to develop a
preliminary SAR analysis (Figure 3). Therefore, the 3,4-dihy-
droquinazolines represent avalidated TryR inhibitor seriesand a
hit expansion program was initiated.
Biological Characterization of the Hit Series. A more
detailed kinetic analysis (Figure S2 of the Supporting In-
formation) established that 1a is a linear competitive inhibitor
ofTryR(withrespecttotrypanothionedisulfide),withaKivalue
of 0.92 ( 0.06 μM, in reasonable agreement with the IC50 value
determinedinthehigh-throughputassay(Table1).Therefore,it
is possible that the 3,4-dihydroquinazolines are binding to TryR
in an orientation that partially occludes the substrate binding
pocket.Compound1aisaselectiveTryRinhibitorbecauseitwas
inactive against human GR (IC50 >100 μM), the nearest human
homologue of TryR. This is consistent with 1a binding to the
negatively charged substrate-binding pocket of TryR, in contrast
Figure 3. SAR derived from screening analogues 1a n (Table 1).
Table 2. N3-Substituted 3,4-Dihydroquinazoline Analogues
and Their Inhibitory Activities against T. brucei TryR and in
Cell-Based Assays
IC50 (μM) EC50 (μM)
R
3 n TryR T. brucei MRC5
1c CO2Me 1 9.4
6a Ph 1 0.93 13 46
6b Ph 2 2.0
6c 2-OMe-Ph 1 1.1
6d 2-F-Ph 1 0.94 14 36
6e 3-Cl-Ph 1 3.5
6f 3-CF3-Ph 1 1.5
6g 3-NMe2-Ph 1 0.81 6.4 27
6h 4-Me-Ph 1 1.3
6i 4-Cl-Ph 1 2.2
6j 4-CF3-Ph 1 2.2
6k Me 1 1.2
9a N-piperidine 2 1.8 1.3 14
9b N-morpholine 2 2.8
9c N-4-Me-piperazine 2 0.93
a 4.4 4.6
9d NMe2 2 3.5
9e NMe2 3 1.0 2.7 2.7
9f NHMe 2 2.0
21 OH 2 1.7
aTryR Ki = 0.32 ( 0.01 μM.
Table 1. Inhibitory Activities of Commercially Available





6 TryR IC50 (μM)
1a CH3 CO2CH3 Ph Br 6.8
a
1b CH3 CO2CH3 Ph CH3 67
b
1c CH3 CO2CH3 Ph Cl 9.4
1d CH3 CO2CH3 Br >100
1e CH3 CO2CH2CH3 Ph Br 12
1f CH3 CO2HP h B r 3 7
1g CH3 CONHNH2 Ph Br 15
1h CH2CH3 CO2CH3 Ph Br 23
1i CH2-N-morpholine CO2CH3 Ph Br 89
1j CH2CH2-N-morpholine CO2CH3 Ph Br 93
1k Ph CO2CH3 Ph CH3 >100
1l 3,4,5-OCH3 phenyl CO2CH3 Ph CH3 >100
1m  CH2NHCO  Ph Br 37
1n  CH2CH2NHCO  Ph Br 39
aT. cruzi TryR IC50 =1 9μM.
bT. cruzi TryR IC50 =3 8μM.6519 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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to the positively charged pocket in GR. Analogue 1a was assayed
against bloodstream form T. brucei and found to have an EC50 of
40 μM representing a >5-fold reduction in potency between the
biochemicalandcellassay.Inacounter-screenagainstamammalian
cellline(MRC5cells),1awasfoundtobeinactive(EC50>50μM).
This is consistent with 1a being inactive against GR.
Hit Expansion. Screening of commercial analogues demon-
strated that the C6-bromine could be replaced with a chlorine
atom without a significant loss of activity (1a vs 1c, Table 1).
This beneficial reduction in molecular weight together with the
availability of starting material 2a resulted in all further com-
pound arrays consisting of analogues with a C6-chlorine sub-
stitution (except where C6 was the point of variation). Initial
synthesis aimed to identify a replacement for the potentially
labileesterfunctionalityof1c.Therefore,benzylanalogues6a j,
amineanalogues 9a f,andalcohol-containing analogue21were
prepared (Table 2, Scheme 1, and Schemes S1 and S2 of the
Supporting Information). Analogues 6a j, 9a f, and 21 all
demonstrated an improved potency with respect to ester 1c in
the T. brucei TryR assay, including examples showing a 10-fold
improvement (6a, 6d, 6g, and 9c). However, there is only a
4-fold difference in potency between the most and least potent
analoguesinthetwoarrays(6gvs6e/9d),resultinginaflatSAR.
To improve potency, a chemistry-driven, systematic SAR
analysis was performed to investigate the N3-, C4-, C6-, and
C8-positions. Additional functionality at the C2-position had
been shown to result in a large reduction of potency (1i 1l,
Table 1, Figure 3), so was not further investigated.
To probe the N3-position, amide derivatives of analogues 9f
and 9c were prepared (11a h and 13a h, Scheme 2 and
Scheme S3 of the Supporting Information). These amides
retained their TryR inhibitory activity (Table 3), but there was
a narrow range of potencies (IC50 0.37 2.6 μM), giving no
identiﬁable SAR. Compounds 11e and 13h were found to have a
mixed mode of inhibition, although comparison of their Ki and
Ki
0 values show that they bind to the free enzyme more readily
thantotheenzyme T[S]2complex,similar tothemodeof inhi-




 1 per non-H atom, respectively).
Table 3. SubstitutedAmide3,4-Dihydroquinazoline Analogues andTheirInhibitoryActivities against T.bruceiTryRandinCell-
Based Assays
aTryR Ki = 0.44 ( 0.03 μM, Ki
0 = 2.27 ( 0.3 μM.
bTryR Ki = 0.27 ( 0.02 μM, TryR Ki
0 = 1.78 ( 0.3 μM.
Table 4. C6-Substituted and C8-Substituted 3,4-Dihydro-
quinazoline Analogues and Their InhibitoryActivities against
T. brucei TryR and in Cell-Based Assays




8 TryR T. brucei MRC5
9a 1 N-piperidine Cl H 1.8 1.3 14
15b 1 N-piperidine H H 0.78 12 23
15c 1 N-piperidine Br H 0.79 0.44 8.4
15d 1 N-piperidine I H 0.35 0.55 6.8
16a 1 N-piperidine Ph H 7.3 0.75 3.4
16b 1 N-piperidine 4-pyridine H 4.4
16c 1 N-piperidine 2-furan H 1.3
16d 1 N-piperidine 3-thiophene H 0.79
16e 1 N-piperidine 1-naphthyl H 8
16f 1 N-piperidine 2-benzo(b)furan H 8.5
18 2 NMe2 Cl Br 53
19 2 NMe2 Cl Ph 246520 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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When investigating the C6-position (Scheme 3, Table 4), the
N3esterwasreplacedwithamorepotentbasicmoiety(e.g.,9avs1c).
The potency of analogues 1a and 15c demonstrated that a
bromine atom was tolerated at C6 (Tables 1 and 4). Therefore,
the C6-position was explored by introducing aryl substituents,
prepared as outlined in Scheme 3. The C6-aryl analogues all
demonstrated low micromolar TryR IC50 values (Table 4),




some activity (16e,f) suggests that the protein does not entirely
occlude the C6 position of the inhibitor upon binding. In
addition, the observation that the C6-bromine analogue
(15c) is 10-fold more potent than the similarly sized C6-
phenyl analogue (16a) implies that the beneﬁcial eﬀect of a
bromine substitution is not entirely due to its steric bulk and
hydrophobic character.
The C8-substituted analogues (18 and 19) were signiﬁcantly
less active when assayed against TryR (Table 4), suggesting that
the introduction of a large hydrophobic group at C8 is detri-
mental to the inhibitor's ability to bind to TryR.
As the chemistry-driven approach failed to identify inhibitors
with improved ligand eﬃciency, protein crystallographic inves-
tigationswereinitiatedinordertofacilitateanalternativerational
inhibitor design program. The SAR expanded to include the
analoguesinTables2 4aboveissummarizedinFigureS3ofthe
Supporting Information.
X-ray Crystallography, Analysis of Ligand Binding, and




Figure 4. The X-ray protein crystal structure of 1a in complex with T. brucei TryR. (A) and (B) show two orientations, rotated about 90, of the
TryR compound 1a complex active site showing experimental density (magenta) for the inhibitor contoured at 2.5 σ. Compound 1a is shown in blue
and FAD in turquoise. Carbon atoms are shown in brown, oxygens in red, nitrogens in dark blue, and sulfurs in yellow. Important residues have been
highlighted in black including Trp21 and Met113, forming the hydrophobic wall and electron donor Glu18. Those residues involved in binding the
halogen componentarelabeledingreen,andthoseinvolvedinthenovelhydrophobicpocketareinblue.(C)Showsthesamecomplexwiththesolvent
accessible surface shown in beige and the ligand in green to demonstrate where the inhibitor is occupying subpockets within the active site cleft.
(D)Surfacerepresentation ofTryRactivesitecleftwithboundcompound1a.ThestructureofT[SH]2(yellow)boundtoTryRfromPDBentry 2wow
has been overlaid.6521 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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This represents the first report of a high resolution noncovalent
small molecule protein X-ray crystal structure for TryR. In
addition, the X-ray crystal structures of nonliganded TryR
(2woi), TryR in complex with NADPH (2wov), and TryR in
complex with trypanothione dithiol and NADPH (2wow) have
been determined. All of the TryR structures reported herein are
in complex with FAD. Ramachandran analyses of the structures
show more than 99% of residues are in the allowed regions in all
models. The few residues outside these regions correspond to
Tyr45, which is known to reside in a strained loop region of all
otherTryRstructuresandArg331,themainchainofwhichisalso
held in astrained conformationinsome TryR structures. See the
Supporting Information (sections 3.2 3.5) for a detailed dis-
cussion of the comparison between the T. brucei TryR X-ray
structures reported in this manuscript and other TryR structures
previously reported in the literature.
ExaminationoftheTryR 1acomplexrevealedthattheligand
binds in a region of the enzyme’s active site cleft that would
normally be occupied by the Gly-I and spermidine moieties of
T[S]2 (Figure 4D). Therefore, the observed binding mode is
consistent with the mode of inhibition of 1a being competitive
with respect to T[S]2 as described above.
The most interesting feature of the TryR 1a structure is the
observation that the enzyme undergoes an induced conforma-
tional change upon inhibitor binding. This conformational
change generates a new subpocket within the active site, which
accommodates the C4-phenyl of 1a (Figure 4C). Previously, the
active site of TryR was believed to be a rigid structure,
40 formed
by residues that belong to a congregation of α-helices. Accord-
ingly, the substrate T[S]2 is highly ﬂexible and adopts a con-
formation to accommodate the rigid active site. However, upon
binding of 1a, the Met113 side chain moves approximately 5 Å
outward into the active site, creating a new hydrophobic pocket.
ThissubpocketislinedbyLeu120,Phe114,Val33,Leu17,Ala12,
Val9, Val31, and Leu48. The entrance to the subpocket is
“guarded” by Trp21, Met113, and Tyr110. This induced ﬁt had
not previously been predicted in TryR, and the signiﬁcant
movement of the Met113 side chain clearly changes the proper-
ties of the active site, thus aﬀecting the binding of T[S]2. The
bound inhibitor not only sterically impedes the binding of the
spermidine moiety of T[S]2 but also alters the shape of the
hydrophobic patch that normally binds this substrate moiety.
The orientation of 1a in the active site anchors it tightly in
position; the large bromine atom pushes against one end of the
cleft and Trp21 interacts with the N3 substitution (see below)
actingasaphysicalbarrier,preventingtheinhibitorfromlocating
further up the opposite side of the cleft. There is only one
hydrogen bonding interaction with the protein from N1 to the
Oε1 of Glu18 (2.7 Å). The bromine atom of 1a sits in an area of
the active site cleft surrounded by Gly13, Ser14, Leu17, Gly49,
Val53, and Tyr110. The catalytic Cys52 is situated at this end of
this region and sits 6.7 Å from the C6-bromine. In the non-
liganded structure, the area in which the bromine atom binds is
instead occupied by a water molecule. The large size of the
subpocketaroundthebromineatomisconsistentwithanalogues
16e and 16f that contain bicyclic aromatic substituents at C6
retaining some, albeit reduced, potency (IC50 8.0 and 8.5 μM,
respectively, Table 4).
The C4-phenyl group of 1a protrudes into the hydrophobic
regionformerlyoccupiedbyMet113.Thephenylgroupsitsatan
angleof 108 tothe planeof the dihydroquinazoline core. In this
position, the phenyl group makes an edge face hydrophobic
interaction with Tyr110, which has rotated 62 from the non-
liganded structure. Although one of the weakest hydrophobic
interactions,
41 it still contributes binding energy to the inhibitor
complex.TheresidueswithinvanderWaalsinteractingdistances
(4 Å) from this phenyl group and likely to be participating in
hydrophobic interactions include Met113, Trp21, Tyr110,
Leu17,Phe114,and Leu120(Figure4A,B).The synthetic routes
tosubstituteddihydroquinazolinesthatwereutilizedinthisstudy
(Scheme 1) result in analogues that are racemic at C4. However,
the ligand binding mode described above allows only the 4S-
enantiomertoeﬀectivelyoccupytheinduced-ﬁtsubpocketcreated
by the movement of Met113.
The methyl acetate moiety of 1a is directed out into the active
site cleft and sits 3.1 Å from Met113Sδ. It is within 3.5 Å of, and
stacks against, Trp21, which has pivoted about Cδ1 to move
the indole group 1.0 Å closer to the inhibitor when compared to
the nonliganded structure. This helps to wedge the inhibitor in
Figure 5. The crystallographically determined binding orientations of compounds 6a, 11e, 13e, and 29a overlaid in the active site of the TryR 1a
complex structure. 1a is displayed in cyan, 6a in orange, 11e in magenta, 13e in green, and 29a in yellow. The 3,4-dihydroquinazoline and phenyl ring
systems overlay well, while the more variable and ﬂexible N3-substituents point out into the active site opening in a variety of orientations.6522 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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position. The C2-methyl of 1a also stacks with Trp21Cδ1a ta
distance of 3 Å, helping to stabilize the inhibitor in this position.
The binding mode of 1a is consistent with 1i 1l showing
weakornoinhibitoryactivity(IC5089to>100μM)againstTryR
(Table 1, Figure 3). These analogues contain bulky substitu-
tions at C2 that would prevent ligand binding due to occlusion
of this position by the protein. Similarly, compounds 18 and 19
(Table 4) display reduced potency (IC50 53 and 24 μM,
respectively) due to a steric clash between their C8 substituents
and the surface of the active site cleft (Figure 4C).
Residues Glu18, Trp21, and Met113, which form key inter-
actionswith1a,arenotconservedinhumanGR(seeFigureS4of
the Supporting Information), which is consistent with the fact
that 1a is not an inhibitor of the human enzyme (see above).
Interestingly, the irreversible TryR inhibitor quinacrine mustard
(Figure S7 of the Supporting Information) has also been shown
to bind to the same hydrophobic area of the protein.
26 Despite
binding in the same region as 1a, the binding of quinacrine
mustard does not induce a conformational change in the active
site of TryR. A more detailed comparison of the TryR 
dihydroquinazoline complex with the published TryR quina-
crine structures is discussed in section 3.4 of the Supporting
Information.
TohelprationalizetheSARderivedfromthedihydroquinazo-
line analogues, additional protein ligand complexes were struc-
turally characterized. To investigate the N3 substitution TryR
complexes with analogues 6a, 11e, and 13e were solved. Un-
fortunately, no complexes with analogues containing C6-aryl
substitutions could be determined.
Comparison of the complexes for compounds 6a, 11e, and
13e with that for 1a show that the 3,4-dihydroquinazoline core
superimposes in identical positions and that the C6-halogen
substitutionsoverlaywithoneanother(Figure5).Therefore,the
N3 substitution does not have any signiﬁcant eﬀect on the
position of ligand binding. In analogue 6a, the N3 acetyl ester
group has been replaced with a benzyl group, resulting in a 10-
fold increase in potency (6a IC50 = 0.93 μMv s1c IC50 = 9.4
μM). Interestingly, the benzyl group does not stack against
Trp21 but is angled such that it is pointing away from the side
chain of Trp21and into the active sitecleft in asimilarfashionto
the methyl acetate of 1a and so does not appear to contribute to
inhibitor binding. In compounds 11e and 13e, the ester moiety
hasbeenreplacedwithsubstitutedamides,giving11-and22-fold
improvements inpotency(IC500.86and0.42 μM,respectively).
In 11e and 13e, the N3-substituent runs along the surface of the
protein, forming hydrophobic interactionswithTrp21 and other
residues. The displacement of water molecules from the protein
surfaceandtheresultanthydrophobicinteractionsarelikelytobe
the major eﬀect contributing to the improvement in potency
observed with these analogues, as there are no other speciﬁc
molecular interactions between the protein and the additional
N3-amide functionality. The lack of speciﬁc molecular interac-
tions between TryR and the N3-substituent of 11e/13e is
consistent with the relatively ﬂat SAR observed from screening
6a j, 9a f, 11a h, and 13a h (Tables 2 and 3).
Structure-Based Inhibitor Design. Although numerous
modeling studies
15,16,21 26,42 52 have predicted binding modes
for various classes of TryR inhibitors, the accuracy of these
models has not been corroborated by structure-based experi-
ments and do not consider the ability of Met113 to undergo a
conformational change as observed upon binding of 1a. There-
fore, the current study represents a unique opportunity to
perform a validated structure-assisted inhibitor design project
for TryR.
Examination of the TryR ligand structures suggested three
primary areas for further investigation: (1) the eﬀect of altering
the halogen substitution at C6, (2) challenging the hydrophobic
pocket created by the movement of Met113 by altering the C4
phenyl moiety, and (3) reducing the size of the N3 substitution
to improve ligand eﬃciency.
Comparison of the halogens and hydrogen at the C6-positon
(9a, 15b d) (Table 4) indicated that they were approximately
equipotent. Therefore, 3,4-dihydroquinazoline-based inhibitors
do not need to occupy the Ser14, Leu17, Gly49, and Val63
subpocket (Figure 4A) toeﬀectively inhibit TryR, providing that
15b binds in an analogous fashion to 1a.
To investigate the eﬀect of challenging the induced subpocket
with additional steric bulk, compound 29a, containing a para-
toluene substituent at C4, was prepared as outlined in Scheme
4 and assayed against TryR (Table 5). The introduction of
the additional methyl group resulted in a 4-fold improvement
in potency (cf. 9e,I C 50 = 1.0 μM, Table 2), suggesting that
additional hydrophobic interactions in the subpocket are
beneﬁcial for ligand binding. Structural determination of the
TryR 29a complex revealed that the overall eﬀect of introdu-
cingthemethylgroupistopushtheinhibitorfurtheroutintothe
activesiteby0.5Å(Figure5).TheC6-chlorineandN1atomsact
as anchor points, having moved only 0.5 Å, whereas the C4-aryl
Table 5. C4-Substituted 3,4-Dihydroquinazoline Analogues
and Their Inhibitory Activities against T. brucei TryR and in
Cell-Based Assays
IC50 (μM) EC50 (μM)
n R
3 R
4 X TryR T. brucei MRC5
29a 2 NMe2 4-Me-Ph H 0.23
a 0.73 1.9
29b 1 N-piperidine 4-
tBu-Ph H 7.9
29c 1 N-piperidine 3-F-Ph H 0.9 2 10
29d 1 N-piperidine 3-OMe-Ph H 28
29e 1 N-piperidine 3,4-Cl2-Ph H 1.3
29f 1 N-piperidine cyclohexyl H 27
31b 1 N-piperidine 4-F-Ph OH 8.3
31c 1 N-piperidine 4-OMe-Ph OH 4.9
31d 1 N-piperidine 4-Me-Ph OH 0.71 1.5 5.7
32a 1 N-piperidine 4-Cl-Ph H 0.73
32b 1 N-piperidine 4-F-Ph H 4.9
32c 1 N-piperidine 4-OMe-Ph H 1.5
32d 1 N-piperidine 4-Me-Ph H 0.59 1.4 5.0
32e 1 N-piperidine 3-Cl-Ph H 1.2
32f 1 N-piperidine 3-Me-Ph H 4.6
32g 1 N-piperidine 3,4-Me2-Ph H 6.8
34 1 N-piperidine Bn H 50
35 1 N-piperidine 4-OH-Ph H 20
36 1 N-piperidine 4-OH-Ph H 1.6
aTryR Ki = 0.19 ( 0.01 μM, Ki
0 = 1.46 ( 0.32 μM.6523 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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ring has moved outward by 1.0 Å toward the mouth of the active
site. To accommodate this outward movement, the phenol side
chain of Tyr110 rotates through 30. The combination of this
side chain rotation and inhibitor translation brings the phenyl
group of 29a closer to Tyr110 by 0.5 Å when compared to
compounds 1a, 6a, 11e, and 13e (Figure 5), allowing stronger
hydrophobic stacking interactions to occur. Therefore, the 4-
fold improvement in potency can be attributed to stronger
hydrophobicinteractionsfromoccupyingmoreofthesubpocket
and being closer to Tyr110. A more detailed kinetic analysis of
29a revealed that its mode of inhibition is linear mixed with
respect to trypanothione, compared to linear competitive for 1a.
However, comparison of the Ki and Ki
0 values for 29a (Table 5)
shows that 29a has a greater aﬃnity to the free enzyme than
to the enzyme T[S]2 complex and so is behaving in a similar
manner to 1a.
To further explore the subpocket, a small collection of
analogues containing a C4-aryl (29b e, 32a g, 35, and 36), a
C4-cyclohexyl (29f), or a C4-benzyl (34) substituent were
prepared and tested (Table 5). All of the analogues in this
collection contained an N-ethylpiperidine substitution at N3 in
order to make them directly comparable to the majority of the
other dihydroquinazolines prepared in this study. The ortho-
substituted analogue 1d was known to be inactive (Table 1),
probably due to the additional steric bulk of the ortho-chlorine
atom, preventing the C4 substituent from occupying the in-
duced-ﬁtsubpocket.Therefore,allofthephenylderivativeswere
substituted at the meta and/or para positions. However, none of
the aryl analogues (29b e, 32a c, 32e g, 35, and 36) showed
any improvement in potency compared to the para-tolyl ana-
logue 32d (Table 5). Increasing the size of the para-substituent
to a tert-butyl group (29b) gives an analogue which retains
activity, albeit less active than the para-hydrogen analogue (9a).
This suggests that either the induced-ﬁt pocket can accommo-
date larger hydrophobic groups or that the ligand can bind
further away from the top surface of the induced subpocket,
although either hypothesis must result in suboptimal ligand
binding. This is supported by the observation that the para-
methoxy and para-chloro analogues (32c and 32a) are equipo-
tent to 9a. The meta-methoxy analogue 29d is 15-fold less active
than9a,suggestingthattheproteincannotreadilyaccommodate
additional stericbulk inthat region of thesubpocket. There is no
clear relationship between the electronic character of the aryl
substituent and TryR inhibitory activity, with the meta-ﬂuoro
(29c) and para-ﬂuoro (32b) displaying a 5-fold diﬀerence in
potency, which cannot be attributed to sterics. The 4-cyclohexyl
analogue 29f is 15-fold less active than the 4-Ph analogue (9a),
consistent with the observation that a 4-aryl substituent con-
tributes to binding aﬃnity by forming an edge face interaction
with Tyr110. Similarly, the 4-benzyl analogue 34 is less potent
than9a.Threeofthe4-OHintermediatesontheroutetothe3,4-
dihydroquinazolines (31b d, Scheme 5) were also assayed
against TryR (Table 5) and found to retain activity, albeit at a
slightly reduced level compared to their reduced counterparts
(32b d, respectively). This is consistent with the observed
binding mode of the ligands, which suggests that the additional
hydroxyl group would point out into the solvent exposed active
site and as a result neither enhance nor impede ligand binding.
The SAR (Figure S3 of the Supporting Information) and
TryR ligand complexes suggest that the N3-substituent makes
no signiﬁcant contribution to inhibitor binding. Therefore,
quinazolines 6k and 21, which have truncated N3-substituents,
were assayed against TryR and found to be equipotent with
analogues containing large R
3-groups (6a j, 9a f, Table 2).
The reduction in substitution size results in compounds with
improved ligand eﬃciencies (6k = 0.41 kcal mol
 1 per non-H
atom) and reduced polar surface area.
Cell Screening. Selected dihydroquinazoline analogues were
screened against both bloodstream form T. brucei parasites and
MRC5 cells in whole cell assays (Tables 2 5). Analogues were
selected such that representative examples of each array were
screened. For the larger arrays, the most potent TryR inhibitors
were preferentially triaged to the cell assays.
All of the dihydroquinazoline analogues that were screened
demonstrated antitrypanosomal activity greater than that for the
hit compound (1a), consistent with them all being more potent
TryR inhibitors. However, there is a poor correlation between
the TryR IC50 and the T. brucei EC50, with some analogues (9a,
15c, 16a) having T. brucei EC50 values lower than their corre-
sponding IC50 values. This suggests that some analogues are not
exerting all of their antitrypanosomal activity through inhibition
of TryR. The selectivity within the series (as judged by MRC5
EC50/T.bruceiEC50)variesfrom∼1to∼20,thepoorselectivity
of some analogues being consistent with oﬀ-target activities. It is
hoped that, as this series is further optimized against TryR there
will be a concomitant reduction in the oﬀ-target eﬀects and an
increase in selectivity. Alternatively, the detailed understanding
of the ligand binding mode may facilitate the identiﬁcation of
alternative inhibitor scaﬀolds with greater selectivity.
It is possible to identify some trends from analysis of the cell
screeningdata.ThenatureoftheN3-substituenthasalargeeﬀect
upon both the selectivity and T. brucei EC50:TryR IC50 ratio.
Most analogues which contain a basic N3-functionality (9c,e,
11e,h, and 13e,h) have poor selectivity (0.92 2.3). In addition,
the amide-containing analogues (11e,h and 13e,h) display the
largest (>15-fold) drop oﬀ between their enzyme and cellular
inhibition values. However, 9a, which contains an ethylpiper-
idine N3-substituent, does not follow this trend, instead being
11-fold selective. Analogues lacking a basic substitution at N3
(1a, 6a,d,g) show reduced cell activity in both assays, suggesting
that overall the amine substituent is increasing oﬀ-target activity
or is important for cellular uptake. However, although the N3
moiety has an eﬀect upon selectivity and IC50:EC50 ratio within
the series, it does notmake any signiﬁcantcontributions to TryR
binding (Figure 5).
Compounds 9a, 15c, and 15d, which vary only in their C6-
halogen substituent, all display similar activities in all assays
(Table 4). However, analogue 15b (R6 =H )i s∼10-fold less
potent against T. brucei and as a result signiﬁcantly less selective.
This suggests that the nonspeciﬁc antitrypanosomal activity is in
part related to the hydrophobicity of the inhibitors (calculated
LogD pH 7.4; 15b = 2.1, 15d = 3.2). Compound 16a, which
containedaC6phenylsubstituent,is10-foldmorepotentagainst
T. brucei cells than it is against TryR (Table 4), identifying this
inhibitorasactingprimarilyoﬀ-target.Inaddition,16aisalsoone
of the most potent analogues in the MRC5 assay.
Dihydroquinazoline 29a, the most potent analogue against
TryR (Ki = 0.19 μM, Ki
0 = 1.46 μM), is also one of the most
potent against T. brucei (EC50 = 0.73 μM), demonstrating that
improved TryR potency can drive antitrypanosomal activity. All
C4-substituted analogues (29a,c, 31d,a n d32d)r e t a i nt h e i r
antitrypanosomal activity (Table 5 cf. 9a), in contrast with analo-
gues containing large N3-substitutions (11e,h and 13e,h,T a b l e3 ) ,6524 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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despite both sets of compounds having similar TryR inhibitory
activities (Tables 3 and 5).
The current level of antitrypanosomal activity and selectivity
against mammalian cells is insuﬃcient to test these compounds
in an animal model of infection. Therefore, continued develop-
mentisrequired toidentifyalead compoundfromthis hit series.
’CONCLUSIONS
Large and open active site pockets such as that found in TryR
are diﬃcult targets to eﬀectively inhibit with small drug-like
molecules. To date, no high-resolution, noncovalent enzyme 
inhibitorcomplexesofTryRhavebeenstructurallycharacterized,
further limiting attempts to develop potent, low molecular
weight inhibitors. In this study, we have reported the crystal
structures of T. brucei TryR in complex with a noncovalently
bound inhibitor series based around a 3,4-dihydroquinazoline
scaﬀold. In addition, the structure of T. brucei TryR in complex
with the cofactors FAD, NADPH, and reduced trypanothione is
presented. The results describe a novel and small hydrophobic
pocket generated upon inhibitor binding that lies within a
“privileged”region of thelargeactivesite pocket.Itisanticipated
that these results will facilitate the area of TryR inhibitor design
andassistinthegenerationoffurtherprotein inhibitorcomplex
structures which until now have relied mainly on in silico
modeling and docking studies. Given the urgent need for new
HAT therapeutics, we hope that the structural information
reported herein will accelerate the development of TryR inhibi-
tors and possibly identify new drug leads.
In addition to the crystallographic studies, we have reported
the identiﬁcation and characterization of a novel TryR inhibitor
series based upon the 3,4-dihydroquinazoline ring system. From
hit compounds 1a and 1b, a systematic SAR study has expanded
theseriestoinclude>75analogues(Tables1 5,Figures3and6,
and Figure S3 of the Supporting Information). A chemistry-
driven approach was used to identify compounds which were
more potent than 1a in both the TryR biochemical and T. brucei
cell assays (cf. 1a and 13h, Figure 6). However, the analogues
developed by this strategy contained large N3-substitutions,
resulting in high molecular weight inhibitors which were un-
suitable for further optimization. The structural elucidation of
ligand TryR complexes allowed us to subsequently adopt a
structure-based inhibitor design approach, which was used to
develop compounds with both improved TryR and T. brucei
inhibitory activities (cf. 1a and 29a, Figure 6) while maintaining
ligand eﬃciencies >0.3 kcal mol
 1 per non-H atom (6k, 29a,
Figure 6). As the dihydroquinazoline series underwent develop-
ment, the mode of inhibition changed from competitive to
mixed (cf. 1a and 13h/29a, Figure 6 and see Figure S2 of the
Supporting Information). The development of a mixed inhibitor
is potentially advantageous, as these are more resistant to
substrate accumulation, a feature that could be important due
to the high intracellular concentration of trypanothione.
To our knowledge, compound 29a is the most potent, drug-
like inhibitor of TryR reported to date. However, this series
requires further optimization to improve its cellular potency and
selectivity. Because of their high ligand eﬃciencies and low
molecularweights, analogues29aand6krepresent goodstarting
Figure 6. Summary of the development of hit compound 1a by an initial chemistry-driven approach and subsequent structure-based inhibitor design
strategy. The units for ligand eﬃciencies (Lig. eﬀ.) are kcal mol
 1 per non-hydrogen atom.6525 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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points for further structure-based drug design. The hit-to-lead
development of the 3,4-dihydroquinazoline inhibitor series is
summarized in Figure 6.
’EXPERIMENTAL SECTION
Chemicals and solvents were purchased from the Aldrich Chemical
Co., Fluka, ABCR, VWR, Acros, Fisher Chemicals, and Alfa Aesar and
were used as received unless otherwise stated. Air- and moisture-
sensitive reactions were carried out under an inert atmosphere of argon
in oven-dried glassware. Analytical thin-layer chromatography (TLC)
was performed on precoated TLC plates (layer 0.20 mm silica gel 60
with ﬂuorescent indicator UV254, from Merck). Developed plates were
air-dried and analyzed under a UV lamp (UV254/365 nm). Flash
column chromatography was performed using prepacked silica gel
cartridges (230 400 mesh, 40 63 μm, from SiliCycle) using a Tele-
dyne ISCO Combiﬂash Companion, or Combiﬂash Retrieve.
1H NMR,
13C NMR,
19F NMR, and 2D-NMR spectra were recorded on a Bruker
Avance DPX 500 spectrometer (
1H at 500.1 MHz,
13C at 125.8 MHz,
19F at 470.5 MHz). Chemical shifts (δ) are expressed in ppm recorded
using the residual solvent as the internal reference in all cases. Signal
splitting patterns are described as singlet (s), doublet (d), triplet (t),
quartet (q), multiplet (m), broad (br), or a combination thereof.
Coupling constants (J) are quoted to the nearest 0.5 Hz. LC-MS
analyses were performed with either an Agilent HPLC 1100 series
connectedtoaBrukerDaltonicsMicrOTOForanAgilentTechnologies
1200 series HPLC connected to an Agilent Technologies 6130 quad-
rupole LC/MS, where both instruments were connected to an Agilent
diode array detector. LCMS chromatographic separations were con-
ducted with a Waters Xbridge C18 column, 50 mm   2.1 mm, 3.5 μm
particle size; mobile phase, water/acetonitrile +0.1% HCOOH, or
water/acetonitrile +0.1% NH3; linear gradient 80:20 to 5:95 over 3.5
min, and then held for 1.5 min; ﬂow rate 0.5 mL min
 1. All assay
compounds had a measured purity of g95% as determined using this
analytical LC-MS system (TIC and UV). High resolution electrospray
measurements were performed on a Bruker Daltonics MicrOTOF mass
spectrometer. Microwave-assisted chemistry was performed using a
Biotage Initiator microwave synthesizer.
Method A (Compounds 3a e). Pyridine (1.2 equiv) was added
to a solution of the relevant 2-aminobenzophenone analogue, DMAP
(cat.),andtherelevantacidchlorideinanhydrousCH2Cl2andstirredat
25 C for 16 h. The reaction mixture was then added to a solution of
NaOH (2.0M, aq), the layers separated, and the aqueous extracted with





EtOH and the reaction mixture heated at 160 C for 1 h in a microwave
reactor.
Method C1 (Compounds 5a c,h,i, 8a,b). NaBH4 (20 equiv)
was added to a solution of the appropriate imine in anhydrous DMF
(2mL)andheatedat60Cfor16h.Thereactionwasthenquenchedby
theadditionofwater(1mL)andsubsequentlyextractedintoEt2O(3 
5 mL). The workup was completed as outlined in method A. Note that
the amine products were observed to slowly convert to the cyclic
amidines when in solution.
Method C2 (Compounds 6d g,j,k 9a,c e). NaBH4 (20
equiv) was added to a solution of the appropriate imine in EtOH and
heated at 78 C for 16 48 h. The reaction was then quenched by the
addition of an aqueous solution of citric acid (10% w/v), the EtOH
removed under reduced pressure, and the pH of the remaining aqueous
adjusted to ∼10 before being extracted with CH2Cl2. The workup was
completed as outlined in method A.
Method D (Compounds 6a c,h,i, 9a,b). POCl3 (5 equiv) was
added to a solution of the relevant amine in CHCl3 and heated at 61 C
for 16 24 h. The reaction mixture was added to a solution of NaOH
(2.0M, aq), the layers separated, and the aqueous extracted with
CH2Cl2. The workup was completed as outlined in method A.
Method E (Compounds 11b h and 13b h). HCl (4.0 M in
dioxane, 40 equiv) was added to a solution of Boc protected amine 11a
or13ainanhydrousTHFandstirredat25Cfor2.5hbeforeremovalof
the solvent under reduced pressure. The crude amine was then redis-
solved in CH2Cl2/pyridine (4:1), to whichwas added DMAP(cat.) and
the relevant benzoyl chloride (2 equiv). The reaction was subsequently
heated at 40 C for 16 h, after which the reaction mixture was added to
a solution of NaOH (2.0M, aq), the layers separated and the aque-
ous extracted with CH2Cl2. The workup was completed as outlined in
method A.
Method F (Compounds 18, 19a f). Pd(PPh3)4 (0.03 equiv)
wasaddedtoadegassedsolutionconsistingoftherelevantarylbromide,
therelevantboronicacid,andK3PO4(2equiv)indioxane/water(10:1).
Subsequently, the reaction was heated at 120 C for 30 min in a
microwave reactor, followed by evaporation of the solvents under
reduced pressure.
Method G (Compounds 26b e). n-BuLi (19.4 mmol, 1.6 M in
hexanes, 12.1 mL) was added to a solution of the relevant aryl bromide
(17.6 mmol) in anhydrous Et2O (20 mL) at  78 C. Subsequently, the
reaction was allowed to warm to 0 C over 2 h, after which a solution of
5-chloro anthranilate (23) (4 mmol, 686 mg) in dry THF (30 mL) was
added totheresultantaryllithiumandthereactionstirredforafurther2
hat0C.WorkupwasinitiatedbytheadditionofTMSCl(10mL),and
the reaction was allowed to warm to 25 C over 15 min. Subsequently,
1N HCl (aq, 30 mL) was added and the mixture stirred at 25 C for a
further 15 min. The biphasic mixture was then separated and the
aqueous layer neutralized and extracted into Et2O( 3  50 mL). The
workup was completed as outlined in method A.
Method H (Compounds 31a g). The appropriate Grignard
reagent (8 mmol) was added to a solution of quinazolinone (30)
(2 mmol, 612 mg) in anhydrous THF (10 mL) at 0 C. The reaction
was thenallowed towarmto25 C over2h beforeworkupwasinitiated
bytheadditionofNaClsolution(satdaq20mL).Theresultantmixture
was filtered and the solids washed with EtOAc (2   10 mL). Subse-
quently, the biphasic filtrate was separated and the pH of the aqueous
layeradjustedto10priortofurtherextractionwithEtOAc(3 50mL).
The workup was completed as outlined in method A.
Method I (Compounds 32b d,g). BF33OEt2 (40 equiv) and
HSiEt3 (40 equiv) were sequentially added to a solution of the relevant
alcohol in CH2Cl2 and the reactions stirred at 25 C for 60 h. Workup
wasinitiatedbytheadditionofNaClsolution(satdaq),thepHofwhich
was adjusted to 10 prior to the layers being separated and the aqueous
further extracted with CH2Cl2. The workup was completed as outlined
in method A.
Synthesis and Analysis of Selected Compounds. N-(2-
Benzoyl-4-chlorophenyl)acetamide (3a). Prepared according to
method A from 2-amino-5-chlorobenzophenone (2a)( 2 3 . 2g ,1 0 0
mmol) and acetyl chloride (9.42 g, 120 mmol). The crude product
was purified by recrystallization from EtOAc/hexane to give a white
solid (21.5 g, 79%).
1H NMR (500 MHz, CDCl3): δ 10.63 (br s, 1H,
NH), 8.61 (d, 1H, J =9 . 0H z ,H - 6 ) ,7 . 7 1  7.69 (m, 2H, 2   ArH),
7.66 7.62 (m, 1H, ArH), 7.54 7.50 (m, 4H, 4   ArH), 2.22 (s, 3H,
CH3).
13C NMR (125 MHz, CDCl3): δ 198.5 (C), 169.2 (C), 138.9
(C), 137.9 (C), 134.0 (CH), 133.1 (CH), 132.6 (CH), 129.9 (CH),
128.6 (CH), 127.3 (C), 124.6 (C), 123.1 (CH), 25.3 (CH3). LRMS
(ES+): m/z (%) 232 (67) [
35Cl M   Ac + H]
+, 234 (22) [
37Cl M  
Ac + H]
+,2 7 4( 1 0 0 )[
35Cl M + H]
+, 276 (42) [
37Cl M + H]
+.
N-(2-((Benzylimino)(phenyl)methyl)-4-chlorophenyl)acetamide
(4a). Prepared according to method B from benzylamine (129 mg,6526 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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1.2 mmol) and N-(2-benzoyl-4-chlorophenyl)acetamide (3a) (274 mg,
1 mmol) in EtOH (3 mL). Upon cooling, the product crystallized from
the crude reaction mixture and was subsequently recovered by filtration
and washed with cold EtOH (2   5 mL) to give a white crystalline solid
(89 mg, 25%).
1H NMR (500 MHz, CDCl3): δ 13.32 (br s, 1H, NH),
8.70 (d, 1H, J = 9.0 Hz, ArH), 7.59 7.54 (m, 3H, 3   ArH), 7.38 7.35
(m,2H,2 ArH),7.33 7.28(m,4H,4 ArH),7.23 7.21(m,2H,2 
ArH),6.91(d,1H,J=2.5Hz,H-3),4.51(s,2H,CH2),1.82(s,3H,CH3).
13C NMR(125MHz,CDCl3):δ 171.5(C), 169.6(C),139.5(C),139.1
(C),135.3(C),132.3(CH),131.0(CH),129.3(CH),129.1(CH),128.7
(CH),128.1(CH),127.4(CH),126.7(C),124.4(C),121.8(CH),57.9
(CH2), 25.0 (CH3). LRMS (ES+): m/z (%) 363 (100) [
35Cl M + H]
+,
365 (41) [
37Cl M + H]
+.
(R/S)-N-(2-((Benzylamino)(phenyl)methyl)-4-chlorophenyl)aceta-
mide (5a). Prepared according to method C1 from N-(2-((benzyli-
mino)(phenyl)methyl)-4-chlorophenyl)acetamide (4a) (109 mg, 0.3
mmol). The crude product was purified by flash column chromatogra-
phy(EtOAc/hexane0:100f50:50)togiveacreamsolid(48mg,44%).
1HNMR(500MHz,CDCl3):δ11.0(brs,1H,NH),8.22(d,1H,J=8.5
Hz, ArH), 7.32 7.15 (m, 10H, 10   ArH), 7.04 7.02 (m, 1H, ArH),








(6a). Prepared according to method D from N-(2-((benzylamino)-
(phenyl)methyl)-4-chlorophenyl)acetamide (5a) (48 mg, 0.13 mmol).
The crude product was purified by triturating from Et2O (40 mg, 87%).
1H NMR (500 MHz, CDCl3): δ 7.69 (d, 1H, J = 8.5 Hz, ArH),
7.48 7.42 (m, 6H, 6   ArH), 7.27 7.23 (m, 3H, 3   ArH),
7.19 7.17 (m, 1H, ArH), 6.77 (d, 1H, J = 2.0 Hz, H-5), 5.53 (s, 1H,
H-4), 4.89 (d, 1H, J = 16.0 Hz, CHH), 4.29 (d, 1H, J = 16.0 Hz, CHH),
2.81 (s, 3H, CH3).
13C NMR (125 MHz, CDCl3): δ 158.4 (C), 139.2
(C), 133.1 (C), 131.4 (C) 130.2 (CH), 130.1 (CH), 129.91 (CH),
129.88 (CH), 129.5 (CH), 128.2 (C), 127.3 (CH), 126.9 (CH), 126.8
(CH), 122.2 (C), 120.5 (CH), 62.3 (CH), 52.2 (CH2), 18.5 (CH3).
LRMS (ES+): m/z (%) 347 (100) [
35Cl M + H]
+, 349 (34) [
37Cl M +
H]




yl)acetamide (7a). Prepared according to method B from 1-(2-ami-
noethyl)piperidine (154 mg, 1.2 mmol) and N-(2-benzoyl-4-chloro-
phenyl)acetamide (3a) (274 mg, 1 mmol). The reaction solvent was
removed under reduced pressure and purified by column chromatogra-
phy (MeOH/CH2Cl2 0:100 f 10:90) to give a white solid (210 mg,
54%).
1H NMR (500 MHz, CDCl3): δ 13.56 (br s, 1H, NH), 8.72 (d,
1H,J=9.0Hz,H-6),7.51 7.45(m,3H,3 ArH),7.29(dd,1H,J=9.0,
3.0 Hz, H-5), 7.12 7.10 (m, 2H, 2   ArH), 6.83 (d, 1H, J = 3.0 Hz,
H-3), 3.43 (t, 2H, J = 7.0, CH2), 2.66 (t, 2H, J = 7.0, CH2), 2.37 2.28
(m, 4H, 2   CH2), 2.24 (s, 3H, CH3), 1.55 1.51 (m, 4H, 2   CH2),
1.43 1.38 (m, 2H, CH2).
13C NMR (125 MHz, CDCl3): δ 171.8 (C),
169.6(C),139.2(C),135.5(C),132.1(CH),130.8(CH),129.1(CH),
129.0 (CH), 127.1 (CH), 126.6 (C), 124.3 (C), 121.6 (CH), 60.2
(CH2), 54.8 (CH2), 51.1 (CH2), 25.9 (CH2), 25.5 (CH3), 24.3 (CH2).
LRMS (ES+): m/z (%) 192.5 (24) [
35Cl M + 2H]
2+, 384 (100) [
35Cl
M+H ]
+, 386 (31) [
37Cl M + H]
+.
(R/S)-6-Chloro-2-methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-3,4-
dihydroquinazoline (9a). Prepared according tomethodC2 or method
D. Method C2 from N-(4-chloro-2-(phenyl(2-(piperidin-1-yl)ethyli-
mino)methyl)phenyl)acetamide (7a) (360 mg, 0.94 mmol) in EtOH
(5 mL): The crude product was purified by flash column chromatog-
raphy (0.5 M NH3 in MeOH/CH2Cl2 1:100 f 4:96) to give a cream
solid (211 mg, 61%). Method D from N-(4-chloro-2-(phenyl(2-




5H, 5   ArH), 7.05 (dd, 1H, J = 8.5, 2.5 Hz, H-7), 6.99 (d, 1H, J =8 . 5
Hz, H-8), 6.74 (d, 1H, J = 2.5 Hz, H-5), 5.53 (s, 1H, H-4), 3.43 (ddd,
1H, J = 14.5, 8.5, 6.0 Hz, CHH), 3.16 (ddd, 1H, J = 14.5, 8.5, 6.0 Hz,
CHH), 2.50 (ddd, 1H, J =12.5, 8.5,6.0Hz,CHH), 2.38 2.28 (m, 5H,
CHHe a n d2  CH2), 2.26 (s, 3H, CH3), 1.55 1.51 (m, 4H, 2  
CH2), 1.43 1.37 (m, 2H, CH2).
13C NMR (125 MHz, CDCl3): δ
156.4 (C), 143.7 (C), 139.6 (C), 129.1 (CH), 128.7 (C), 128.4 (CH),
128.3 (CH), 126.7 (CH), 126.3 (C), 126.0 (CH), 125.0 (CH), 63.2





37Cl M + 2H]
2+, 368 (100) [
35Cl M + H]
+, 370 (35) [
37Cl M +
H]
+. HRMS (ES+): calcd for C22H27ClN3 [M + H]
+ 368.1888, found
368.1888 ( 0.01 ppm).
(R/S)-tert-Butyl 2-(6-Chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)-
ethylcarbamate (11a). Two identical reactions containing N-(2-ben-
zoyl-4-chlorophenyl)acetamide (3a) (1.37 g, 5.0 mmol) and N-Boc-(2-
aminoethyl)amine (1.19mL,7.5mmol)inEtOH(20mL)werereacted
according to method B. The two reactions were then combined and
diluted with EtOH (60 mL) and reacted directly according to method
C2. The product was purified by column chromatography (MeOH/
CH2Cl2 2:98 f 10:90) to give a white solid (1.19 g, 30%).
1H NMR
(500 MHz, CDCl3): δ 7.33 7.26 (m, 5H, 5   ArH), 7.08 (dd, 1H, J =
8.5, 2.0 Hz, H-7), 7.05 (d, 1H, J = 8.5 Hz, H-8), 6.76 (d, 1H, J = 2.0 Hz,
H-5), 5.44 (s, 1H, H-4), 3.57 3.52 (m, 1H, CHH), 3.25 3.14 (m, 3H,
CHH and CH2), 2.25 (s, 3H, CH3), 1.40 (s, 9H, 3   CH3).
13C NMR
(125MHz,DMSO-d6):δ156.6(C),155.9(C),143.3(C),129.3(CH),
129.1 (C), 128.6 (CH), 128.5 (CH), 126.6 (CH), 126.1 (CH), 126.0
(C), 125.0 (CH), 79.9 (C), 62.5 (CH), 48.4 (CH2), 38.2 (CH2), 28.3
(CH3), 22.3 (CH3). LRMS (ES+): m/z (%) 400 (100) [
35Cl M + H]
+,
402 (41) [
37Cl M + H]
+. HRMS (ES+): calcd for C22H27N3O2 [M +
H]




(120 mg, 0.3 mmol) and benzoyl chloride (84 mg, 0.6 mmol). The
product was purified by flash column chromatography (0.5 M NH3
MeOH/CH2Cl20:100f10:90)togiveaclearglass(53mg,44%).
1H
NMR(500MHz,CDCl3):δ7.68 7.66(m,2H,2 ArH),7.53 7.50
(m, 1H, ArH), 7.44 7.41 (m, 2H, 2   ArH), 7.36 7.30 (m, 5H, 5  
ArH),7.11(dd,1H,J=8.5,2.5Hz,H-7),7.06(d,1H,J=8.5Hz,H-8),
6.78 (d, 1H, J = 2.5 Hz, H-5), 6.27 (br s, 1H, NH), 5.47 (s, 1H, H-4),
3.68 3.43 (m, 4H, 2   CH2), 2.29 (s, 3H, CH3).
13CN M R( 1 2 5
MHz,DMSO-d6):δ168.0(C),156.5(C),143.6(C),139.4(C),133.7
(C), 132.0 (CH), 129.3 (CH), 129.2 (C), 128.8 (CH), 128.63 (CH),
128.55(CH),126.8(CH),126.5(CH),126.1(C), 126.0 (CH), 125.3
(CH),63.0(CH),48.5(CH2),38.3(CH2),22.6(CH3).LRMS(ES+):
m/z (%) 404 (100) [
35Cl M + H]
+, 406 (35) [
37Cl M + H]
+.H R M S
(ES+): calcd for C24H23N3O1 [M + H]
+ 404.1524, found 404.1520
(1.01 ppm).
Synthesis of (2-Amino-5-bromophenyl)(phenyl)methanone (2c).
NBS (1.87 g, 10.5 mmol) was added to a suspension of 2-aminobenzo-
phenone (1.97 g, 10 mmol) and tosic acid-derivatized silica gel (0.68
mmol/g, 150 mg) in MeCN/Et2O (1:3, 50 mL). The reaction mixture
was stirred for 30 min, filtered, the silica washed with CH2Cl2 (10 mL),
and the combined filtrate removed under reduced pressure. The crude
aryl bromide was purified by flash column chromatography (CH2Cl2)
to give a yellow solid (2.25 g, 82%).
1H NMR (500 MHz, CDCl3):
δ 7.66 7.64 (m, 2H, 2   ArH), 7.60 7.57 (m, 2H, 2   ArH), 7.52 7.49
(m,2H,2 ArH),7.38(dd,1H,J=8.5,2.0Hz,H-4),6.67(d,1H,J=8.5Hz,
H-3), 6.11 (br s, 2H, NH2).
13C NMR (125 MHz, CDCl3): δ 198.0 (C),
149.7 (C), 139.3 (C), 136.9 (CH), 136.2 (CH), 131.6 (CH), 129.1 (CH),
128.4(CH),119.4(C),118.8(CH),106.6(C).LRMS(ES+):m/z(%)276
(100) [
79Br M + H]
+, 278 (100) [
80Br M + H]
+.6527 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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Synthesis of (R/S)-2-Methyl-4,6-diphenyl-3-(2-(piperidin-1-yl)ethyl)-
3,4-dihydroquinazoline (16a). Prepared according to method F from
6-bromo-2-methyl-4-phenyl-3-(2-(piperidin-1-yl)ethyl)-3,4-dihydroqui-





7.40 7.30(m,7H,7 ArH),7.28 7.24(m,2H,2 ArH),7.18(d,1H,
J = 8.0 Hz, ArH), 7.03 (d, 1H, J = 2.5 Hz, ArH), 5.65 (s, 1H, H-4), 3.51
(ddd,1H,J=15.0,9.0,6.0Hz,CHH),3.23(ddd,1H,J=15.0,9.0,6.0Hz,
CHH), 2.57 (ddd, 1H, J = 12.5, 9.0, 5.5 Hz, CHH), 2.44 2.31 (m, 8H,
CHH,2 CH2,CH 3),1.59 1.54(m,4H,2 CH2),1.46 1.41(m,2H,
CH2).LRMS(ES+):m/z(%)410(100)[M+H]
+.HRMS(ES+):calcd
for C28H32N3 [M + H]
+ 410.2591, found 410.2599 ( 2.08 ppm).
(R/S)-3-(6-Chloro-2-methyl-4,8-diphenylquinazolin-3(4H)-yl)-N,N-
dimethylpropan-1-amine (19). Prepared according to general method
E from 3-(6-bromo-8-chloro-2-methyl-4-phenylquinazolin-3(4H)-yl)-
N,N-dimethylpropan-1-amine (18) (42 mg, 0.1 mmol) and phenyl-
boronic acid (12 mg, 0.1 mmol). The crude product was purified by
preparative HPLC to give a white solid (17 mg, 41%).
1H NMR (500
MHz,CDCl3):δ7.64 7.62(m,2H,2 ArH),7.41 7.37(m,2H,2 
ArH),7.32 7.25(m, 6H,6 ArH),7.16(d,1H, J=2.5Hz,ArH),6.79
(dd,1H,J=2.5,0.5Hz,ArH),5.48(s,1H,CH),3.46(ddd,1H,J=14.5,
8.5, 6.0 Hz, CHH), 3.11 (ddd, 1H, J = 14.5, 8.5, 6.0 Hz, CHH),
2.33 2.22(m,5H,CH2andCH3),2.20(s,6H,2 NCH3),1.82 1.65
(m, 2H, CH2).
13C NMR (125 MHz, CDCl3): δ 156.0 (C), 143.9 (C),
138.7(C),137.4(C),136.9(C),130.5(CH),129.5(CH),129.1(CH),
128.3 (CH), 127.7 (CH), 127.4 (C), 127.0 (CH), 126.6 (CH), 125.1
(CH), 62.6 (CH), 56.3 (CH2), 46.8 (CH2), 45.4 (CH3), 26.3 (CH2),
22.9(CH3).[Note:onequaternarycarbonresonanceisabsent,possibly
due to it having anidentical chemicalshift to another quaternary carbon
resonance]. LRMS (ES+): m/z (%) 209.5 (42) [
35Cl M + 2H]
2+, 210.5
(13) [
37Cl M + 2H]
2+, 418 (100) [
35Cl M + H]
+, 420 (38) [
37Cl M +
H]





to a solution of benzoxazinone (24) (1.96 g, 10 mmol) in anhydrous
THF (40 mL) at 0 C. The reaction mixture was allowed to warm to
25 C over 30 min and stirred for an additional 1.5 h before the reaction
was quenched by the addition of NaCl solution (satd aq 50 mL). The
resultantbiphasicmixturewasseparatedandtheaqueouslayerextracted
with EtOAc (3   50 mL). Subsequently, the combined organic layers
were dried over MgSO4, filtered, and the solvent removed under
reduced pressure. The crude product was purified by flash column




ArH), 7.51 7.49 (m, 2H, 2   ArH), 7.32 7.30 (m, 2H, AA0BB0,2 
ArH), 2.46 (s, 3H, CH3), 2.21 (s, 3H, CH3).
13C NMR (125 MHz,
CDCl3): δ 198.0 (CO), 169.1 (C), 144.1 (C), 138.7 (C), 135.1 (C),
133.6 (CH), 132.4 (CH), 130.2 (CH), 129.3 (CH), 127.2 (C), 125.0
(C), 123.1 (CH), 25.2 (CH3), 21.7 (CH3). LRMS (ES+): m/z (%) 288
(100) [
35Cl M + H]
+, 290 (31) [




N-(4-chloro-2-(4-methylbenzoyl)phenyl)acetamide (27a) and 3-(di-
methylamino)-1-propylamine. The crude product was purified by flash
columnchromatography oversilica(0.5MNH3inMeOH/CHCl31:99
f 4:96) to give a white solid (485 mg, 65%).
1H NMR (500 MHz,
CDCl3): δ 13.66 (s, 1H, NH), 8.71 (d, 1H, J = 9.0 Hz, H-6), 7.29 7.25
(m,3H,AA0BB0 andH-5),6.99 6.97(m,2H,AA0BB0),6.86(d,1H,J=
2.5 Hz, H-3), 3.33 (t, 2H, J = 7.0 Hz, CH2), 2.42 (s, 3H, CH3), 2.30 (t,
2H, J = 7.5 Hz, CH2), 2.21 (s, 3H, CH3), 2.19 (s, 6H, 2   CH3),
1.89 1.84 (m, 2H, CH2).
13C NMR (125 MHz, CDCl3): δ 171.7 (C),
169.3 (C), 139.1 (C), 138.9 (C), 132.4 (C), 132.2 (CH), 130.6 (CH),
129.6 (CH), 127.1 (CH), 126.6 (C), 124.4 (C), 121.5 (CH), 57.7
(CH2), 51.8 (CH2), 45.6 (CH3), 29.7 (CH2), 25.4 (CH3), 21.4 (CH3).
LRMS (ES+): m/z (%) 186.5 (100) [
35Cl M + 2H]
2+, 187.5 (32) [
37Cl
M + 2H]
2+, 372 (61) [
35Cl M + H]
+, 374 (18) [





nyl)acetamide (28a). The crude product was purified by flash column
chromatography over silica (MeOH/CH2Cl2 0:100 f 10:90) to give a
clear gum (99 mg, 28%).
1H NMR (500 MHz, CDCl3): δ 7.20 7.17
(m, 2H, AA0BB0,2   ArH), 7.15 7.13 (m, 2H, AA0BB0,2  ArH), 7.09
(dd,1H,J=8.5,2.5Hz,H-7),7.05(d,1H,J=8.5Hz,H-8),6.77(d,1H.
J = 2.5 Hz, H-5), 5.46 (s, 1H, H-4), 3.46 (ddd, 1H, J = 14.5, 8.0, 6.5 Hz,
CHH), 3.11 (ddd, 1H, J = 14.5, 8.5, 6.0 Hz, CHH), 2.33 (s, 3H, CH3),
2.30 (s, 3H, CH3), 2.29 2.21 (m, 2H, CH2), 2.20 (s, 6H, 2   NCH3),
1.81 1.64 (m, 2H, CH2).
13C NMR (125 MHz, CDCl3): δ 156.5 (C),
140.9 (C), 139.8 (C), 138.1 (C), 129.7 (CH), 128.7 (C), 128.2 (CH),
126.6 (CH), 126.5 (C), 126.0 (CH), 125.1 (CH), 62.1 (CH), 56.2
(CH2), 46.8 (CH2), 45.4 (CH3), 26.2 (CH2), 22.4 (CH3), 21.1 (CH3).
LRMS (ES+): m/z (%) 178.5 (27) [
35Cl M + 2H]








+ 356.1888, found 356.1881 (1.84 ppm).
(2-Amino-5-chlorophenyl)(4-tert-butylphenyl)methanone (26b).
Prepared according to general method G from 1-bromo-4-(tert-bu-
tyl)benzene (3.75 g, 17.6 mmol). The final product was purified by
flash column chromatography over silica (EtOAc/hexanes 0:100 f
50:50) to give a yellow solid (679 mg, 59%).
1H NMR (500 MHz,
CDCl3): δ 7.61 7.58 (m, 2H, AA0BB0,2  ArH), 7.50 7.48 (m, 2H,
AA0BB0,2  ArH), 7.47 (d, 1H, J = 2.5 Hz, H-6), 7.24 (dd, 1H, J = 9.0,
2.5 Hz, H-4), 6.69 (d, 1H, J = 9.0 Hz, H-3), 1.37 (s, 9H, 3   CH3).
13C
NMR (125 MHz, CDCl3): δ 197.8 (CO), 155.3 (C), 149.2 (C), 136.4
(C), 133.9 (CH), 133.2 (CH), 129.3 (CH), 125.3 (CH), 120.0 (C),
119.2 (C), 118.4 (CH), 35.1 (C), 31.2 (CH3). LRMS (ES+): m/z (%)
288 (100) [
35Cl M + H]
+, 290 (33) [
37Cl M + H]
+.
4-(4-tert-Butylphenyl)-6-chloro-2-methyl-3-(2-(piperidin-1-yl)ethyl)-
3,4-dihydroquinazoline (29b). Prepared in three steps from 26b,a c e t y l
chloride,and1-(2-aminoethyl)piperidinefollowinggeneralmethodsA,B,
andC2.ThefinalproductwaspurifiedbyreversephasepreparativeHPLC
to give a white solid (40 mg, 6% over 3 steps).
1H NMR (500 MHz,
CDCl3): δ 7.33 7.31 (m, 2H, AA0BB0), 7.21 7.19 (m, 2H, AA0BB0),
7.07 (dd,1H, J=8.5,2.0Hz,H-7),7.01(d, 1H,J=8.5Hz,H-8),6.77(d,
1H,J=2.0Hz,H-5),5.51(s,1H,H-4),3.45(ddd,1H,J=14.5,8.5,6.0Hz,
CHH), 3.20 (ddd, 1H, J = 14.5, 8.5, 6.0 Hz, CHH), 2.52 (ddd, 1H, J =
13.0,8.5,6.0Hz,CHH),2.40 2.31(m,5H,CHHand2 CH2),2.28(s,
3H,CH3),1.58 1.53(m,4H,2 CH2),1.45 1.40(m,2H,CH2),1.29
(s,9H,3 CH3).
13CNMR(125MHz,CDCl3):δ156.4(C),151.2(C),
140.9 (C), 139.9 (C), 128.6 (C), 128.2 (CH), 126.5 (C), 126.3 (CH),







+. HRMS (ES+): calcd for C26H35
35Cl1N3 [M + H]
+ 424.2514,




8 mL, 8 mmol). The final product was purified by recrystallization from
MeCN to give a white solid (339 mg, 41%).
1H NMR (500 MHz,
CDCl3): δ 9.48 (br s, 1H, OH), 7.49 7.46 (m, 2H, AA0BB0,2  ArH),
7.35 7.32 (m, 2H, AA0BB0,2  ArH), 7.14 (dd, 1H, J = 8.5, 2.5 Hz,
H-7), 7.11 (d, 1H, J = 8.5 Hz, H-8), 6.79 (d, 1H, J = 2.5 Hz, H-5),
3.51 3.47 (m, 1H, CHH), 3.10 3.05 (m, 1H, CHH), 2.60 2.55 (m,
1H, CHH), 2.50 2.45 (m, 2H, 2   CHH), 2.35 2.31 (m, 3   CHH6528 dx.doi.org/10.1021/jm200312v |J. Med. Chem. 2011, 54, 6514–6530
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andCH3),1.72 1.68(m,4H,2 CH2),1.54 1.48(m,2H,CH2).
13C
NMR (125 MHz, CDCl3): δ 153.5 (C), 145.4 (C), 138.2 (C), 133.9
(C), 129.10 (C), 129.08 (C), 128.7 (CH), 128.5 (CH), 128.1 (CH),
127.4 (CH), 125.4 (CH), 85.2 (C), 58.9 (CH2), 54.6 (CH2), 43.9
(CH2), 25.2 (CH2), 23.6 (CH2), 23.2 (CH3). LRMS (ES+): m/z (%)
418 (100) [
35Cl2 M+H ]
+, 420 (64) [
35Cl
37Cl M + H]
+.
6-Chloro-4-(4-chlorophenyl)-2-methyl-3-(2-(piperidin-1-yl)ethyl)-
3,4-dihydroquinazoline (32a). Prepared according to general method I
from dihydroquinazolinol (31a) (42 mg, 0.1 mmol). The final product
was purified from the crude reaction mixture by flash column chroma-
tography over silica (MeOH/CH2Cl2 0:100 f 10:90) to give a clear
glass(31mg,77%).
1HNMR(500MHz,CDCl3):δ7.35 7.33(m,2H,
AA0BB0,2  ArH), 7.25 7.22 (m, 2H, AA0BB0,2  ArH), 7.15 7.11
(m, 2H, H-7 and H-8), 6.78 (d, 1H, J = 1.5 Hz, H-5), 5.76 (s, 1H, H-4),
3.52 (ddd, 1H, J = 15.0, 6.5, 6.5 Hz, CHH), 3.29 3.24 (m, 1H, CHH),
2.59 2.53 (m, 1H, CHH), 2.48 2.26 (m, 8H, CHH, CH3 and 2  
CH2), 1.57 1.53 (m, 4H, 2   CH2), 1.44 1.39 (m, 2H, CH2).
13C
NMR (125 MHz, CDCl3): δ 157.5 (C), 140.7 (C), 135.0 (C), 130.6
(C), 129.70 (CH), 129.2 (CH), 128.2 (CH), 126.2 (CH), 124.4 (C),
122.9 (CH), 62.9 (CH), 57.2 (CH2), 55.1 (CH2), 47.3 (CH2), 26.0
(CH2), 24.0 (CH2), 21.0 (CH3). Note: HMBC analysis suggests that
the quaternary carbon peak at 135.0 results from two quaternary carbon





37Cl M + H]
+. HRMS (ES+): calcd for C22H26
35Cl2N3 [M + H]
+
402.1498, found 402.1501 ( 0.62 ppm).
Biology. TryR Enzyme Assay. Compounds were assayed against
recombinantTryRfromT.bruceibruceistrainS427,whichwasexpressed
and purified as previously described.
35 Potency was determined as
independent duplicates for all compounds tested as previously.
9,12 A
serial titration of clomipramine was used as a positive control in each
assay plate: BTCP was used as an additional control in some screening
plates. ActivityBase from IDBS was used for all data processing and
analysis.Someinhibitorswerescreenedina96-wellformatessentiallyas
above. The assay was assessed for robustness, yielding the following
typical performance statistics: Z0 = 0.84 ( 0.001; %CV (plate) = 3.65 (
0.4; S:B = 10 ( 0.25; IC50 (clomipramine) = 12.4 ( 0.14 μm. All
reported IC50 values are the mean of at least two replicates, with the
standard deviations typically being less than 20% of the mean.
Cell Assays. Compounds were assayed against bloodstream form
T. brucei brucei and MRC5 cells using resazurin fluorescence-based
viability assays as previously described. All reported EC50 values are the
mean of at least two replicates, with the standard deviations typically
being less than 50% of the mean. The HAT drug pentamidine was
present in all T. brucei plates as a positive control. Pentamidine has an
EC50 of 5 nM (n > 1000) in this assay, which is in close agreement with
published EC50 values.
37
Mode of Inhibition Studies. These were determined as previously
described using a DTNB-coupled assay.
12 Briefly, the assay mixture
contained150μMNADPH,50μMDTNB,and20mUmL
 1TryRand
was initiated by the addition of T[S]2 ranging from 0.58 to 50 μM. The
linear rate of increase in absorbance at 412 nm was determined using a
Molecular Devices Thermomax plate reader. Each data set was fitted by
nonlinear regression to the Michaelis Menten equation using GraFit
5.0 (Erithacus software). The resulting individual fits were examined as
Lineweaver Burke transformations and the graphs inspected for diag-
nostic inhibition patterns. The entire data set was then globally fitted to
the appropriate equation (competitive, mixed, or uncompetitive in-
hibition)andgoodness-of-fitbetweenmodelscomparedusingtheF-test
(see Figure S2 of the Supporting Information for an example).
Cloning, Expression, and Purification of His-Tagged TryR. The gene
corresponding to T. brucei trypanothione reductase was cloned into a
pET15bvector(Novagen)foroverexpressionwitha6-histidinetag.The
plasmid was transformed into Escherichia coli strain BL21 (DE3) codon
plus RIL. Cells were cultured in autoinduction media for 3 days and
harvested by centrifugation. The cell pellet was resuspended in 25 mM
Tris-HCl,pH8.0, 500mMNaBr,and5mMimidazoleandlysedusinga
French Press at 16000 psi. Insoluble debris was removed by centrifuga-
tion at 40000g for 20 min and the soluble lysate clarified by filtration
through a 0.2 μm syringe filter. Ni
2+ affinity chromatography, thrombin
removal of the 6-histidine tag, and Q Sepharose anion exchange
chromatography on an Akta purifier (GE Healthcare) yielded 80 mg
L
 1 of purified protein as assessed by SDS-PAGE. The protein was
dialyzedinto50mMHEPES,pH7.5,50mMNaBr,andconcentratedto
15 mg mL
 1 to be used for crystallography.
Crystallization.Sparsematrixscreens(JenaBiosciences)wereusedto
identify initial crystallization conditions, which were optimized and
refined using the hanging drop vapor diffusion method to 26% MPD,
10% polyethylene glycol 3350, and 40 mM imidazole, pH 8.0. Thin,
plate-typecrystalsgrewin3dayswithdimensions0.3 0.2 0.05mm
3.
The crystallization mother liquor acted as a suitable cryoprotectant
during data collection in which the crystals were cooled to 100 K in a
stream of nitrogen gas. For the inhibitor complex structures, crystals
were soaked for between 2 and 24 h with solid inhibitor compound
introduced into the hanging crystallization drops. Data were collected
both in-house on a Rigaku 007 MicroMax rotating anode X-ray
generator coupled to an R-AXIS IV++ image plate detector and at the
European Synchrotron Radiation Facility on beamlines ID14 2 and
ID14 4. The crystals were space group P21 with cell dimensions of a =
101.8, b = 63.6, c = 169.8 Å, β = 97.9. Data were processed and scaled
using the XDS package,
53,54 and statistics are shown in Table S1 of the
Supporting Information.
Structure Solution, Model Building, And Refinement. The structure
of nonliganded T. brucei TryR was solved by molecular replacement
using MOLREP (CCP4) and the T. cruzi TryR model 1aog
20 [82%
sequence identity]. Matthews coefficient calculations implied that there
were two dimers in the asymmetric unit with a solvent content of 51%,
which were found by MOLREP. COOT
55 was used to correct the
nonidentical residues in the TryR model chain A, which was then
superposed on chain B, C, and D to generate the two dimers in the
asymmetric unit. Further model building and water placement with
COOT was interspersed with refinement with REFMAC5. The non-
liganded protein was used as a template to solve the complex structures
of the inhibitor series and other ligands in the study. Coordinates and





b S Supporting Information. Additional synthetic proce-
dures and analytical information for screening compounds and
selected intermediates. Further discussion of the protein X-ray
crystal structures. All scheme, ﬁgure, table and section numbers
preﬁxed with an ‘S’ are present in the Supporting Information.
Thismaterial isavailablefree ofchargevia theInternetathttp://
pubs.acs.org.
Accession Codes
Coordinates of T. brucei TryR and TryR-ligand complexes have
been deposited at the RSCB Protein Data Bank, (PDB ID codes
2woi, 2wov, 2wow, 2wp5, 2wp6, 2wpc, 2wpe, 2wpf).
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